Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs

Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of di...

Full description

Saved in:

Bibliographic Details
Published in:	Molecules (Basel, Switzerland) Vol. 25; no. 8; p. 1987
Main Authors:	Artasensi, Angelica, Pedretti, Alessandro, Vistoli, Giulio, Fumagalli, Laura
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI 23-04-2020 MDPI AG
Subjects:	Biomarkers diabetes mellitus Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - etiology Diabetes Mellitus, Type 2 - metabolism Disease Susceptibility Drug Design Drug Discovery Drug Evaluation, Preclinical Glucose - metabolism Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Incretins - chemistry Incretins - pharmacology Incretins - therapeutic use Ligands Molecular Targeted Therapy multi-target compounds multi-target drugs Review Structure-Activity Relationship type 2 diabetes mellitus type 2 diabetes mellitus multi-target compounds diabetes mellitus multi-target drugs
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90-95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes. In particular, the review considers the main systems directly involved in T2DM or involved in diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as on peroxisome proliferation activated receptors are considered. Inhibitors which target either aldose reductase and tyrosine phosphatase 1B or sodium glucose transporters 1 and 2 are taken into account. Moreover, with a view at the multi-target approaches for T2DM some phytocomplexes are also discussed.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1420-3049 1420-3049
DOI:	10.3390/molecules25081987